Niagen Bioscience, Inc (NAGE)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Niagen Bioscience, Inc (NAGE) is down 44.3% since the beginning of the year. At $4 per share, NAGE is trading 75.9% below its 52-week high of $15. Investors who bought $1,000 worth of NAGE shares 5 years ago would now be looking at an investment worth $406.

Niagen Bioscience, Inc (NAGE) has returned -44.34% so far this year and -69.82% over the past 12 months. Over the last ten years, NAGE has returned -4.75% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Jul 15, 2008, NAGE's average daily return is +0.43%, while the average monthly return is +4.49%. At this rate, an investment would double in approximately 1.3 years.

Historically, 48% of months were positive and 52% were negative. The best month was Dec 2008 with a return of +431.8%, while the worst month was Oct 2008 at -82.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 10 months.

On a daily basis, NAGE closed higher 42% of trading days. The best single day was Jul 13, 2009 with a return of +275.0%, while the worst single day was Jul 23, 2009 at -70.4%.

Niagen Bioscience, Inc has an annualized alpha of 179.65%, beta of 0.47, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 16, 2008.

• This stock participated in 199.86% of S&P 500 Index downside but only 194.42% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.47 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NAGE ranks 3 for risk / return — in the bottom 3% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Niagen Bioscience, Inc (NAGE) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Niagen Bioscience, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Niagen Bioscience, Inc was 97.00%, occurring on Aug 3, 2009. Recovery took 2911 trading sessions.

The current Niagen Bioscience, Inc drawdown is 81.11%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Niagen Bioscience, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Niagen Bioscience, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.